18 / 19
Page 82
conferenceseries
.com
Volume 7, Issue 4 (Suppl)
J Clin Exp Pathol, an open access journal
ISSN: 2161-0681
Euro Pathology 2017
August 02-03, 2017
13
th
EUROPEAN PATHOLOGY CONGRESS
August 02-03, 2017 Milan, Italy
The new paradigm of precision medicine: Evidence-based clinical oncology
Marilyn M Li
University of Pennsylvania, USA
P
recision medicine is an emerging approach for disease treatment and prevention that takes into consideration the variations
in genomic makeup, environmental exposure, and social economic status of each individual. Evidence-based oncology
integrates the clinical expertise, patient values and the best available evidence, especially the cancer genomic information of a
patient in clinical decision making. Next-generation sequencing (NGS) technologies have revolutionized genomic research by
decreasing the cost of sequencing while increasing the throughput. Clinical application of NGS in cancer can detect clinically
actionable genetic/genomic alterations that are critical for cancer care. In certain cancers, patient risk and prognosis can be
predicted based on the mutation profile identified by NGS. Many targeted therapies have been developed for cancer patients
who bear specific genomic alterations. However, choosing right NGS techniques for appropriate clinical applications can be
challenging, especially in clinical oncology, where the material for testing is often limited and the turn-around time of testing is
frequently constrained to just a few days. Currently, targeted NGS approaches have emerged as the best fit for clinical oncology.
We have developed and validated multiple large NGS panels that allow the detection of single nucleotide variations (SNVs),
small indels, copy number variations (CNVs), and novel fusion genes in different cancers, as well as pathogenic variants
associated with cancer predispositions. These panels have been applied to thousands of clinical cases and have provided critic
genomic information to aid in patient management decision making. Currently, whole exome and whole genome sequencing
are mostly used in cancer research. As the cost of running NGS-based test continues to decrease and software for NGS data
analysis continues to improve, clinical application of whole exome, whole genome, and whole transcriptome sequencing in
precision cancer care is just a matter of time.
Lim5@email.chop.eduJ Clin Exp Pathol 2017, 7:4(Suppl)
DOI: 10.4172/2161-0681-C1-038